Related Experiment Video
Updated: May 16, 2026

08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
A stochastic agent-based model for simulating tumor-immune dynamics and evaluating therapeutic strategies
Yuhong Zhang1, Chenghang Li2, Boya Wang2
1School of Software, Tiangong University, Tianjin 300387, China.
Mathematical Biosciences and Engineering : MBE
|May 14, 2026
Summary
This study introduces a computational model simulating tumor growth and immune responses. Combination therapies, especially targeted therapy with immunotherapy, show the most effective tumor control by overcoming drug resistance.
Area of Science:
- Computational biology
- Cancer research
- Immunology
Background:
- Tumor-immune interactions are critical for cancer progression and treatment success.
- Understanding cellular heterogeneity and spatial dynamics is key to modeling tumor microenvironments.
Purpose of the Study:
- To develop a stochastic agent-based model simulating tumor growth and immune response.
- To evaluate the efficacy of various therapeutic interventions, including combination therapies.
- To analyze determinants of therapeutic efficacy and identify response saturation effects.
Main Methods:
- Developed a 2D agent-based model integrating cellular heterogeneity, spatial interactions, and drug resistance.
- Simulated tumor cells, cytotoxic T lymphocytes, helper T cells, and regulatory T cells.
- Incorporated proliferation, apoptosis, migration, and immune regulation processes.
Main Results:
- Simulations reproduced immune privilege and spatial immune exclusion phenomena.
- All simulated therapies suppressed tumor growth, with combination therapies being most effective.
- Short-term efficacy depends on drug sensitivity, not resistance rates; immunotherapy shows saturation effects.
Conclusions:
- Agent-based models are valuable for understanding complex tumor-immune dynamics.
- The model provides a platform for optimizing cancer treatment strategies.
- Findings highlight the importance of combination therapies and reveal immunotherapy-specific response limitations.

